MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), Amplified on Chromosome 9, Collaborate with p53 Deficiency in Mouse Osteosarcoma Progression
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Osteosarcoma is the primary malignant cancer of bone and particularly affects adolescents and young adults, causing debilitation and sometimes death. As a model for human osteosarcoma, we have been studying p53+/− mice, which develop osteosarcoma at high frequency. To discover genes that cooperate with p53 deficiency in osteosarcoma formation, we have integrated array comparative genomic hybridization, microarray expression analyses in mouse and human osteosarcomas, and functional assays. In this study, we found seven frequent regions of copy number gain and loss in the mouse p53+/− osteosarcomas but have focused on a recurrent amplification event on mouse chromosome 9A1. This amplicon is syntenic with a similar chromosome 11q22 amplicon identified in several human tumor types. Three genes on this amplicon, the matrix metalloproteinase gene MMP13 and the antiapoptotic genes Birc2 (cIAP1) and Birc3 (cIAP2), show elevated expression in mouse and human osteosarcomas. We developed a functional assay using clonal osteosarcoma cell lines transduced with lentiviral short hairpin RNA vectors to show that down-regulation of MMP13, Birc2, or Birc3 resulted in reduced tumor growth when transplanted into immunodeficient recipient mice. These experiments revealed that high MMP13 expression enhances osteosarcoma cell survival and that Birc2 and Birc3 also enhance cell survival but only in osteosarcoma cells with the chromosome 9A1 amplicon. We conclude that the antiapoptotic genes Birc2 and Birc3 are potential oncogenic drivers in the chromosome 9A1 amplicon. [Cancer Res 2009;69(6):2559–67
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New functions for the matrix metalloproteinases in cancer progression
Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
Coussens, L. M., Fingleton, B., & Matrisian, L. M. (2002) · Science · doi:10.1126/science.1067100 · Cited by 2,761
IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB Activation, and TNFα-Dependent Apoptosis
Varfolomeev, E., Blankenship, J. W., Wayson, S. M., Fedorova, A. V., Kayagaki, N., Garg, P., Zobel, K., Dynek, J. N., Elliott, L. O., Wallweber, H. J. A., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.030 · Cited by 1,218
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach
Zender, L., Spector, M. S., Xue, W., Flemming, P., Cordon-Cardo, C., Silke, J., Fan, S.-T., Luk, J. M., Wigler, M., Hannon, G. J., et al. (2006) · Cell · doi:10.1016/j.cell.2006.05.030 · Cited by 1,065
Self-citationBasu, S., Totty, N. F., Irwin, M. S., Sudol, M., & Downward, J. (2003) · Molecular Cell · doi:10.1016/s1097-2765(02)00776-1 · Cited by 843
Osteosarcoma: Anatomic and Histologic Variants
Klein, M. J., & Siegal, G. P. (2006) · American Journal of Clinical Pathology · doi:10.1309/uc6kqhld9lv2kenn · Cited by 386
Overholtzer, M., Rao, P. H., Favis, R., Lu, X.-Y., Elowitz, M. B., Barany, F., Ladanyi, M., Gorlick, R., & Levine, A. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1934852100 · Cited by 193 · cited 2×
“p53 mutations occur in 15% to 30% of human osteosarcomas (7), and the presence of p53 mutations correlates with increased genome instability (8).”
Background
Cited by
Targeting IAP proteins for therapeutic intervention in cancer
Fulda, S., & Vucic, D. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3627 · Cited by 837
“Furthermore, the syntenic murine genomic region encompassing the genes encoding c-IAP1 and c-IAP2 on chromosome 9 is amplified in murine cancer models — for example, in a mouse model of spontaneous osteosarcoma”
BackgroundIAPs: from caspase inhibitors to modulators of NF-κB, inflammation and cancer
Gyrd-Hansen, M., & Meier, P. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2889 · Cited by 790
“Moreover, recurrent amplification of Birc2 and Birc3 also frequently occurs in mouse models of MYC -driven liver cancer and spontaneous osteosarcoma”
BackgroundSurvivin and IAP proteins in cell-death mechanisms
Altieri, D. C. (2010) · Biochemical Journal · doi:10.1042/bj20100814 · Cited by 376
Apoptotic cell signaling in cancer progression and therapy
Plati, J., Bucur, O., & Khosravi-Far, R. (2011) · Integrative Biology · doi:10.1039/c0ib00144a · Cited by 319
Osteosarcomagenesis: Modeling Cancer Initiation in the Mouse
Jones, K. B. (2011) · Sarcoma · doi:10.1155/2011/694136 · Cited by 40
Metadata
- Authors
- Ma, O., Cai, W.-W., Zender, L., Dayaram, T., Shen, J., Herron, A. J., Lowe, S. W., Man, T.-K., Lau, C. C., & Donehower, L. A.
- Venue
- Cancer Research
- Published
- 2009-03-15
- Volume
- 69
- Issue
- 6
- Pages
- 2559-2567
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2024870249
- Cited by
- 103
- References
- 8
- FWCI
- 6.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), Amplified on Chromosome 9, Collaborate with p53 Deficiency in Mouse Osteosarcoma Progression. https://app.cochat.ai/papers/10.1158/0008-5472.can-08-2929
- The paper
- Ma, O., Cai, W.-W., Zender, L., Dayaram, T., Shen, J., Herron, A. J., Lowe, S. W., Man, T.-K., Lau, C. C., & Donehower, L. A. (2009). MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), Amplified on Chromosome 9, Collaborate with p53 Deficiency in Mouse Osteosarcoma Progression. Cancer Research. https://doi.org/10.1158/0008-5472.can-08-2929
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.